Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL

Cancer Cell

Volumn 20, Issue 3, 2011, Pages 357-369

  Mali, Raghuveer Singh ^a   Ramdas, Baskar ^a   Ma, Peilin ^a   Shi, Jianjian ^a   Munugalavadla, Veerendra ^b   Sims, Emily ^a   Wei, Lei ^a   Vemula, Sasidhar ^a   Nabinger, Sarah C ^a   Goodwin, Charles B ^a   Chan, Rebecca J ^a   Traina, Fabiola ^c   Visconte, Valeria ^c   Tiu, Ramon V ^c   Lewis, Timothy A ^d   Stern, Andrew M ^d   Wen, Qiang ^e   Crispino, John D ^e   Boswell, H Scott ^a   Kapur, Reuben ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GENENTECH INC   (United States)

^c TAUSSIG CANCER INSTITUTE   (United States)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; FLT3 LIGAND; MYOSIN LIGHT CHAIN; PHOSPHATIDYLINOSITOL 3 KINASE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHO KINASE;

ACTIN POLYMERIZATION; ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLAST CELL; CELL GROWTH; CELL SURVIVAL; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; HUMAN CELL; LEUKEMIA; LIFESPAN; MOUSE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; ONCOGENE C KIT; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION;

MUS;

EID: 80052576659     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2011.07.016     Document Type: Article

References (54)

1. Adelstein R.S. Regulation of contractile proteins by phosphorylation. J. Clin. Invest. 1983, 72:1863-1866.
2. Baudard M., Marie J.P., Cadiou M., Viguié F., Zittoun R. Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients. Br. J. Haematol. 1994, 86:82-91.
3. Beghini A., Peterlongo P., Ripamonti C.B., Larizza L., Cairoli R., Morra E., Mecucci C. C-kit mutations in core binding factor leukemias. Blood 2000, 95:726-727.
4. Brincker H. Estimate of overall treatment results in acute nonlymphocytic leukemia based on age-specific rates of incidence and of complete remission. Cancer Treat. Rep. 1985, 69:5-11.
5. Butterfield J.H., Weiler D., Dewald G., Gleich G.J. Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk. Res. 1988, 12:345-355.
6. Chian R., Young S., Danilkovitch-Miagkova A., Rönnstrand L., Leonard E., Ferrao P., Ashman L., Linnekin D. Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant. Blood 2001, 98:1365-1373.
7. Daley G.Q., Van Etten R.A., Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990, 247:824-830.
8. de Lanerolle P., Paul R.J. Myosin phosphorylation/dephosphorylation and regulation of airway smooth muscle contractility. Am. J. Physiol. 1991, 261:L1-L14.
9. Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., Heinrich M.C., Tuveson D.A., Singer S., Janicek M., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 2002, 347:472-480.
10. Doran J.D., Liu X., Taslimi P., Saadat A., Fox T. New insights into the structure-function relationships of Rho-associated kinase: a thermodynamic and hydrodynamic study of the dimer-to-monomer transition and its kinetic implications. Biochem. J. 2004, 384:255-262.
11. Druker B.J., Sawyers C.L., Kantarjian H., Resta D.J., Reese S.F., Ford J.M., Capdeville R., Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 2001, 344:1038-1042.
12. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., Lydon N.B., Kantarjian H., Capdeville R., Ohno-Jones S., Sawyers C.L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 2001, 344:1031-1037.
13. Elson E.L. Cellular mechanics as an indicator of cytoskeletal structure and function. Annu. Rev. Biophys. Biophys. Chem. 1988, 17:397-430.
14. Fröhling S., Schlenk R.F., Breitruck J., Benner A., Kreitmeier S., Tobis K., Döhner H., Döhner K. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002, 100:4372-4380. AML Study Group Ulm. Acute myeloid leukemia.
15. Frost M.J., Ferrao P.T., Hughes T.P., Ashman L.K. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol. Cancer Ther. 2002, 1:1115-1124.
16. Fu X., Gong M.C., Jia T., Somlyo A.V., Somlyo A.P. The effects of the Rho-kinase inhibitor Y-27632 on arachidonic acid-, GTPgammaS-, and phorbol ester-induced Ca2+-sensitization of smooth muscle. FEBS Lett. 1998, 440:183-187.
17. Gilliland D.G., Griffin J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002, 100:1532-1542.
18. Graham S.M., Jørgensen H.G., Allan E., Pearson C., Alcorn M.J., Richmond L., Holyoake T.L. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002, 99:319-325.
19. Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., Davies H., Teague J., Butler A., Stevens C., et al. Patterns of somatic mutation in human cancer genomes. Nature 2007, 446:153-158.
20. Han J., Luby-Phelps K., Das B., Shu X., Xia Y., Mosteller R.D., Krishna U.M., Falck J.R., White M.A., Broek D. Role of substrates and products of PI 3-kinase in regulating activation of Rac-related guanosine triphosphatases by Vav. Science 1998, 279:558-560.
21. Hartman A.D., Wilson-Weekes A., Suvannasankha A., Burgess G.S., Phillips C.A., Hincher K.J., Cripe L.D., Boswell H.S. Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation. Exp. Hematol. 2006, 34:1360-1376.
22. Hirota S., Isozaki K., Moriyama Y., Hashimoto K., Nishida T., Ishiguro S., Kawano K., Hanada M., Kurata A., Takeda M., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279:577-580.
23. Jacobs M., Hayakawa K., Swenson L., Bellon S., Fleming M., Taslimi P., Doran J. The structure of dimeric ROCK I reveals the mechanism for ligand selectivity. J. Biol. Chem. 2006, 281:260-268.
24. Kimura K., Ito M., Amano M., Chihara K., Fukata Y., Nakafuku M., Yamamori B., Feng J., Nakano T., Okawa K., et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 1996, 273:245-248.
25. Kitayama H., Kanakura Y., Furitsu T., Tsujimura T., Oritani K., Ikeda H., Sugahara H., Mitsui H., Kanayama Y., Kitamura Y., et al. Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood 1995, 85:790-798.
26. Kiyoi H., Towatari M., Yokota S., Hamaguchi M., Ohno R., Saito H., Naoe T. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998, 12:1333-1337.
27. Koschmieder S., Göttgens B., Zhang P., Iwasaki-Arai J., Akashi K., Kutok J.L., Dayaram T., Geary K., Green A.R., Tenen D.G., Huettner C.S. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood 2005, 105:324-334.
28. Lange B., Valtieri M., Santoli D., Caracciolo D., Mavilio F., Gemperlein I., Griffin C., Emanuel B., Finan J., Nowell P., et al. Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines. Blood 1987, 70:192-199.
29. Leung T., Chen X.Q., Manser E., Lim L. The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton. Mol. Cell. Biol. 1996, 16:5313-5327.
30. Lochhead P.A., Wickman G., Mezna M., Olson M.F. Activating ROCK1 somatic mutations in human cancer. Oncogene 2010, 29:2591-2598.
31. Lugo T.G., Pendergast A.M., Muller A.J., Witte O.N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990, 247:1079-1082.
32. Ma Y., Zeng S., Metcalfe D.D., Akin C., Dimitrijevic S., Butterfield J.H., McMahon G., Longley B.J. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002, 99:1741-1744.
33. Munugalavadla V., Sims E.C., Borneo J., Chan R.J., Kapur R. Genetic and pharmacologic evidence implicating the p85 alpha, but not p85 beta, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis. Blood 2007, 110:1612-1620.
34. Munugalavadla V., Sims E.C., Chan R.J., Lenz S.D., Kapur R. Requirement for p85alpha regulatory subunit of class IA PI3K in myeloproliferative disease driven by an activation loop mutant of KIT. Exp. Hematol. 2008, 36:301-308.
35. Nagata H., Worobec A.S., Oh C.K., Chowdhury B.A., Tannenbaum S., Suzuki Y., Metcalfe D.D. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc. Natl. Acad. Sci. USA 1995, 92:10560-10564.
36. Nakagawa O., Fujisawa K., Ishizaki T., Saito Y., Nakao K., Narumiya S. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett. 1996, 392:189-193.
37. Nakao M., Yokota S., Iwai T., Kaneko H., Horiike S., Kashima K., Sonoda Y., Fujimoto T., Misawa S. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996, 10:1911-1918.
38. Ohashi K., Nagata K., Maekawa M., Ishizaki T., Narumiya S., Mizuno K. Rho-associated kinase ROCK activates LIM-kinase 1 by phosphorylation at threonine 508 within the activation loop. J. Biol. Chem. 2000, 275:3577-3582.
39. Piao X., Bernstein A. A point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells. Blood 1996, 87:3117-3123.
40. Pratz K.W., Sato T., Murphy K.M., Stine A., Rajkhowa T., Levis M. FLT3 mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood 2010, 115:1425-1432.
41. Riento K., Ridley A.J. Rocks: multifunctional kinases in cell behaviour. Nat. Rev. Mol. Cell Biol. 2003, 4:446-456.
42. Sahai E., Marshall C.J. RHO-GTPases and cancer. Nat. Rev. Cancer 2002, 2:133-142.
43. Schuebel K.E., Movilla N., Rosa J.L., Bustelo X.R. Phosphorylation-dependent and constitutive activation of Rho proteins by wild-type and oncogenic Vav-2. EMBO J. 1998, 17:6608-6621.
44. Sebbagh M., Renvoizé C., Hamelin J., Riché N., Bertoglio J., Bréard J. Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing. Nat. Cell Biol. 2001, 3:346-352.
45. Shibuya M., Hirai S., Seto M., Satoh S., Ohtomo E. Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial. J. Neurol. Sci. 2005, 238:31-39. Fasudil Ischemic Stroke Study Group.
46. Shirao S., Kashiwagi S., Sato M., Miwa S., Nakao F., Kurokawa T., Todoroki-Ikeda N., Mogami K., Mizukami Y., Kuriyama S., et al. Sphingosylphosphorylcholine is a novel messenger for Rho-kinase-mediated Ca2+ sensitization in the bovine cerebral artery: unimportant role for protein kinase C. Circ. Res. 2002, 91:112-119.
47. Shtivelman E., Lifshitz B., Gale R.P., Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985, 315:550-554.
48. Somlyo A.P., Somlyo A.V. Signal transduction and regulation in smooth muscle. Nature 1994, 372:231-236.
49. Sumi T., Matsumoto K., Nakamura T. Specific activation of LIM kinase 2 via phosphorylation of threonine 505 by ROCK, a Rho-dependent protein kinase. J. Biol. Chem. 2001, 276:670-676.
50. Terauchi Y., Tsuji Y., Satoh S., Minoura H., Murakami K., Okuno A., Inukai K., Asano T., Kaburagi Y., Ueki K., et al. Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase. Nat. Genet. 1999, 21:230-235.
51. Vemula S., Ramdas B., Hanneman P., Martin J., Beggs H.E., Kapur R. Essential role for focal adhesion kinase in regulating stress hematopoiesis. Blood 2010, 116:4103-4115.
52. Vemula S., Shi J., Hanneman P., Wei L., Kapur R. ROCK1 functions as a suppressor of inflammatory cell migration by regulating PTEN phosphorylation and stability. Blood 2010, 115:1785-1796.
53. Whitman S.P., Archer K.J., Feng L., Baldus C., Becknell B., Carlson B.D., Carroll A.J., Mrózek K., Vardiman J.W., George S.L., et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res. 2001, 61:7233-7239.
54. Zhang Y.M., Bo J., Taffet G.E., Chang J., Shi J., Reddy A.K., Michael L.H., Schneider M.D., Entman M.L., Schwartz R.J., Wei L. Targeted deletion of ROCK1 protects the heart against pressure overload by inhibiting reactive fibrosis. FASEB J. 2006, 20:916-925.